Related references
Note: Only part of the references are listed.Animal models of pituitary neoplasia
K. E. Lines et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas
Misu Lee et al.
CLINICAL CANCER RESEARCH (2015)
Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells
Rong Xie et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
A Aconitum coreanum polysaccharide fraction induces apoptosis of hepatocellular carcinoma (HCC) cells via pituitary tumor transforming gene 1 (PTTG1)-mediated suppression of the P13K/Akt and activation of p38 MAPK signaling pathway and displays antitumor activity in vivo
Ming Liang et al.
TUMOR BIOLOGY (2015)
The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas
Eric Monsalves et al.
ENDOCRINE-RELATED CANCER (2014)
Genetically engineered mouse models of pituitary tumors
David A. Cano et al.
FRONTIERS IN ONCOLOGY (2014)
mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development
H. Peng et al.
ONCOGENE (2013)
Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway
T. Palumbo et al.
ONCOGENE (2013)
PTTG1 Oncogene Promotes Tumor Malignancy via Epithelial to Mesenchymal Transition and Expansion of Cancer Stem Cell Population
Chang-Hwan Yoon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
PITUITARY GLAND New pathways in the pathogenesis of pituitary adenomas
Nicholas F. Marko et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin
Robert P. Carson et al.
NEUROBIOLOGY OF DISEASE (2012)
Expression of PTTG1 and PTEN in endometrial carcinoma: correlation with tumorigenesis and progression
Zhen-Zhong Feng et al.
MEDICAL ONCOLOGY (2012)
PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas
Hadara Rubinfeld et al.
ENDOCRINE (2012)
Lactate Dehydrogenase B Is Critical for Hyperactive mTOR-Mediated Tumorigenesis
Xiaojun Zha et al.
CANCER RESEARCH (2011)
Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin
Amy J. Malhowski et al.
HUMAN MOLECULAR GENETICS (2011)
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
Hidenori Fukuoka et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Pathogenesis of pituitary tumors
Shlomo Melmed
NATURE REVIEWS ENDOCRINOLOGY (2011)
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
Francis X. McCormack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade
Jianhui Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
HMGA2: A pituitary tumour subtype-specific oncogene?
Monica Fedele et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
The Pathogenesis of Pituitary Tumors
Sylvia L. Asa et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
D. Dworakowska et al.
ENDOCRINE-RELATED CANCER (2009)
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors
Yong Lin et al.
ENDOCRINE-RELATED CANCER (2009)
The role of IGF1 on the differentiation of prolactin secreting cells in the mouse anterior pituitary
Tamiki Hikake et al.
JOURNAL OF ENDOCRINOLOGY (2009)
Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin
Cristiane H. Squarize et al.
CANCER RESEARCH (2008)
Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors
Changxue Lu et al.
ENDOCRINOLOGY (2008)
Development of a pituitary-specific cre line targeted to the Pit-1 lineage
Zhirong Yin et al.
GENESIS (2008)
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis
John J. Bissler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Hongbing Zhang et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Pituitary tumor-transforming gene: Physiology and implications for tumorigenesis
George Vlotides et al.
ENDOCRINE REVIEWS (2007)
Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells
G. Vlotides et al.
MOLECULAR ENDOCRINOLOGY (2006)
Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase ras homologue enriched in brain
Jane Yu et al.
CANCER RESEARCH (2006)
Pituitary tumor transforming gene overexpression facilitates pituitary tumor development
Ines Donangelo et al.
ENDOCRINOLOGY (2006)
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity
Monica Fedele et al.
CANCER CELL (2006)
Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis
V Chesnokova et al.
MOLECULAR ENDOCRINOLOGY (2005)
Insulin and IGF-1 regulate the expression of the pituitary tumor transforming gene (PTTG) in breast tumor cells
AD Thompson et al.
FEBS LETTERS (2005)
Enhanced protein kinase B/Akt signalling in pituitary tumours
M Musat et al.
ENDOCRINE-RELATED CANCER (2005)
Early multipotential pituitary focal hyperplasia in the α-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice
RA Abbud et al.
MOLECULAR ENDOCRINOLOGY (2005)
Efficacy of a rapamycin analog (CCI-779) and IFN-γ in tuberous sclerosis mouse models
L Lee et al.
GENES CHROMOSOMES & CANCER (2005)
Effects of rapamycin in the Eker rat model of tuberous sclerosis complex
H Kenerson et al.
PEDIATRIC RESEARCH (2005)
Morphological studies of prolactin-secreting cells in estrogen receptor α and estrogen receptor β knockout mice
G Pelletier et al.
NEUROENDOCRINOLOGY (2003)
A molecular signature of metastasis in primary solid tumors
S Ramaswamy et al.
NATURE GENETICS (2003)
Pituitary tumorigenesis in prolactin gene-disrupted mice
ME Cruz-Soto et al.
ENDOCRINOLOGY (2002)
Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms
KG Schuff et al.
JOURNAL OF CLINICAL INVESTIGATION (2002)
Akt regulates growth by directly phosphorylating Tsc2
CJ Potter et al.
NATURE CELL BIOLOGY (2002)
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
K Inoki et al.
NATURE CELL BIOLOGY (2002)
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-Kinase/Akt pathway
BD Manning et al.
MOLECULAR CELL (2002)
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas
M Fedele et al.
ONCOGENE (2002)
Cre/LoxP-mediated inactivation of the murine Pten tumor suppressor gene
R Lesche et al.
GENESIS (2002)
A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells
DJ Kwiatkowski et al.
HUMAN MOLECULAR GENETICS (2002)
Expression of pituitary-tumour transforming gene in colorectal tumours
AP Heaney et al.
LANCET (2000)